Masimo (MASI) announced the FDA 510(k) clearance of expanded indications for the delta hemoglobin parameters provided with O3 Regional Oximetry. The parameters display relative changes in hemoglobin that can help clinicians identify the underlying mechanisms responsible for changes in tissue oxygen saturation. With this latest clearance, this capability is now available for use in both cerebral and somatic applications as well as for all patient populations, including pediatric and neonatal patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MASI:
- Video: Why Masimo Is Sliding Today
- Buy Rating for Masimo Amid Legal Opportunities and Market Conditions
- BTIG sees buying opportunity in Masimo weakness after Apple Watch news
- Masimo Corp. Earnings Call Highlights Growth and Resilience
- Cautious Outlook on Masimo: Hold Rating Amid Mixed Financial Signals and Strategic Adjustments